| 翻訳と辞書 |
| Pluristem Therapeutics ： ウィキペディア英語版 |
Pluristem Therapeutics
Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas. In 2012 a procedure involving a stem cell treatment developed by Pluristem saved the life of a 7-year-old girl suffering from bone marrow aplasia.
==Corporate history==
Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of stem cell patents he had developed with colleagues from the Weizmann Institute of Science.〔(【引用サイトリンク】url=http://www.marketwatch.com/investing/stock/psti/profile )〕 In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems. In 2007 the name was changed again, this time to Pluristem Therapeutics Inc.〔 Pluristem's shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
In 2007 Pluristem entered into a collaborative research agreement with the Charité medical school in Berlin for a period of five years. In 2012 Pluristem announced that the agreement had been renewed until 2017. Pluristem was awarded an NIS9 million (US$2.4 million) grant from the Office of the Chief Scientist of Israel in January 2012. In April of the same year the company announced the receipt of an additional grant from the Chief Scientist, this time of NIS11.8 million (US$3.2 million).
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Pluristem Therapeutics」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|